ReoPro

Active Ingredient(s): Abciximab
FDA Approved: * December 16, 2003
Pharm Company: * CENTOCOR INC
Category: Blood Thinner (Anticoagulant)

Abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor.[3] While abciximab has a short plasma half-life, due to its stron... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
2 Discussions

Dosage List

Reopro 2 mg/ml Intravenous Injection, Solution
NDC: 0002-7140
Labeler:
Eli Lilly and Company
Reopro 2 mg/ml Intravenous Injection, Solution
NDC: 57894-200
Labeler:
Janssen Biotech, Inc.

Popular Topics

reopro (abciximab) for cardiac ischemic complications

ReoPro(Abciximab) is a monoclonal antibody that blocks the pathway to platelet aggregation and reduces cardiac ischemic ...